Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

18%

3 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

8 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
10(71.4%)
Phase 3
3(21.4%)
Phase 2
1(7.1%)
14Total
Phase 1(10)
Phase 3(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT07016750Phase 3Recruiting

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Role: lead

NCT06999733Phase 1Recruiting

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

Role: lead

NCT06228326Phase 1Recruiting

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Role: lead

NCT05504837Phase 1Recruiting

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Role: lead

NCT06049082Phase 1Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Role: lead

NCT06563414Recruiting

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Role: lead

NCT05970497Phase 1Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT06724900Phase 1Active Not Recruiting

A Study Assessing KB304 for the Treatment of Wrinkles in Women

Role: lead

NCT04540900Phase 1Active Not Recruiting

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Role: lead

NCT04917874Phase 3Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Role: lead

NCT05095246Phase 1Withdrawn

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Role: lead

NCT05735158Phase 2Unknown

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Role: lead

NCT04491604Phase 3Completed

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

Role: lead

NCT03536143Phase 1Completed

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

Role: lead

NCT04214002Withdrawn

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Role: lead

NCT04047732Phase 1Unknown

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Role: lead

NCT04917887Recruiting

Long-Term Follow-up Protocol

Role: lead

All 17 trials loaded